Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program
Executive Summary
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
You may also be interested in...
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
‘Sleeper Issue:’ How Part B Drugs May Be Impacted By Medicare Part D Redesign
If changes to stand-alone Part D plans mandated by the IRA drive a switch to MA plans, the changing enrollment could drive more uptake of physician-administered drugs – but also more utilization management.